CSGALNACT2 and colon adenocarcinoma: Previous studies have confirmed that the abnormal number of different immune cells could affect the tumor's immune response and CSGALNACT2 expression was positively associated with the level of immune cells in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) [23].